OBJECTIVE: The metabolic syndrome predisposes to the development of cardiovascular diseases. Oxidative stress and elevated circulating oxidized low-density lipoprotein (LDL) concentrations are related to cardiovascular disease and proposed to be features of the metabolic syndrome. F2-isoprostanes are lipid peroxidation products and considered the most reliable biomarkers of oxidative stress. METHODS AND RESULTS: Plasma oxidized LDL (oxLDL) and urinary 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha; the major F2-isoprostane) were analyzed in a cross-sectional study of 289 healthy men (62 to 64 years of age). Individuals completed a 7-day dietary record, and fasting plasma insulin, lipid, and lipoprotein concentrations, LDL particle size, and inflammatory markers were determined. National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) criteria were used to define the metabolic syndrome and individuals were grouped according to the number of risk factors for the metabolic syndrome (0, [n=88; 30%]; > or =1, [n=179; 62%], metabolic syndrome [n=22; 8%]). Group comparisons revealed no differences for oxLDL, 8-iso-PGF2alpha, or reported intake of macronutrients, whereas C-reactive protein and interleukin-6 were increased in the metabolic syndrome. LDL cholesterol strongly determined oxLDL in univariate and multivariate analysis, but no relationship to 8-iso-PGF2alpha was found. In turn, 8-iso-PGF2alpha was related to reported intake of fat, fatty acids, and dietary antioxidants. CONCLUSIONS: There were no increases in plasma oxLDL or measures of oxidative stress (urinary 8-iso-PGF2alpha) in these otherwise healthy 63-year-old men with the metabolic syndrome. Furthermore, no relationship between oxLDL and 8-iso-PGF2alpha was found, but our results suggest a role for dietary factors in oxidative stress.
OBJECTIVE: The metabolic syndrome predisposes to the development of cardiovascular diseases. Oxidative stress and elevated circulating oxidized low-density lipoprotein (LDL) concentrations are related to cardiovascular disease and proposed to be features of the metabolic syndrome. F2-isoprostanes are lipid peroxidation products and considered the most reliable biomarkers of oxidative stress. METHODS AND RESULTS: Plasma oxidized LDL (oxLDL) and urinary 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha; the major F2-isoprostane) were analyzed in a cross-sectional study of 289 healthy men (62 to 64 years of age). Individuals completed a 7-day dietary record, and fasting plasma insulin, lipid, and lipoprotein concentrations, LDL particle size, and inflammatory markers were determined. National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) criteria were used to define the metabolic syndrome and individuals were grouped according to the number of risk factors for the metabolic syndrome (0, [n=88; 30%]; > or =1, [n=179; 62%], metabolic syndrome [n=22; 8%]). Group comparisons revealed no differences for oxLDL, 8-iso-PGF2alpha, or reported intake of macronutrients, whereas C-reactive protein and interleukin-6 were increased in the metabolic syndrome. LDL cholesterol strongly determined oxLDL in univariate and multivariate analysis, but no relationship to 8-iso-PGF2alpha was found. In turn, 8-iso-PGF2alpha was related to reported intake of fat, fatty acids, and dietary antioxidants. CONCLUSIONS: There were no increases in plasma oxLDL or measures of oxidative stress (urinary 8-iso-PGF2alpha) in these otherwise healthy 63-year-old men with the metabolic syndrome. Furthermore, no relationship between oxLDL and 8-iso-PGF2alpha was found, but our results suggest a role for dietary factors in oxidative stress.
Authors: K Esposito; M Ciotola; B Schisano; L Misso; G Giannetti; A Ceriello; D Giugliano Journal: J Endocrinol Invest Date: 2006-10 Impact factor: 4.256
Authors: Raymond C-S Seet; Chung-Yung J Lee; Erle C H Lim; Amy M L Quek; Shan-Hong Huang; Chin-Meng Khoo; Barry Halliwell Journal: Diabetes Care Date: 2010-02-25 Impact factor: 19.112
Authors: R Colas; A Sassolas; M Guichardant; C Cugnet-Anceau; M Moret; P Moulin; M Lagarde; C Calzada Journal: Diabetologia Date: 2011-08-17 Impact factor: 10.122
Authors: A Kotronen; V R Velagapudi; L Yetukuri; J Westerbacka; R Bergholm; K Ekroos; J Makkonen; M-R Taskinen; M Oresic; H Yki-Järvinen Journal: Diabetologia Date: 2009-02-13 Impact factor: 10.122
Authors: P Sjögren; J Sierra-Johnson; K Gertow; M Rosell; B Vessby; U de Faire; A Hamsten; M-L Hellenius; R M Fisher Journal: Diabetologia Date: 2007-11-20 Impact factor: 10.122
Authors: Kiriaque B F Barbosa; Ana Carolina P Volp; Helen Hermana M Hermsdorff; Iñigo Navarro-Blasco; M Ángeles Zulet; J Alfredo Martínez; Josefina Bressan Journal: Lipids Health Dis Date: 2011-04-19 Impact factor: 3.876